New adjuvants in evolving vaccine strategies. (Q51007398)

26 March 2018

editorial

0 references

title

New adjuvants in evolving vaccine strategies. (English)

1 reference

26 March 2018

author

Maria Lina Tornesello

series ordinal

2

1 reference

26 March 2018

Luigi Buonaguro

object named as

Luigi Buonaguro

series ordinal

3

0 references

Franco M Buonaguro

series ordinal

1

object named as

Franco M Buonaguro

1 reference

26 March 2018

language of work or name

English

0 references

publication date

24 May 2011

1 reference

26 March 2018

Expert Opinion on Biological Therapy

published in

1 reference

26 March 2018

volume

11

1 reference

26 March 2018

issue

7

1 reference

26 March 2018

page(s)

827-832

1 reference

26 March 2018

Aluminium compounds for use in vaccines

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Virus-like particle vaccines and adjuvants: the HPV paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Induction of S phase and apoptosis by the human papillomavirus type 16 E7 protein are separable events in immortalized rodent fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Mechanism of action of licensed vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

21 January 2018

ISCOMs and ISCOMATRIX.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Influenza virosomes as a vaccine adjuvant and carrier system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

CpG oligodeoxynucleotides as immunotherapy in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

A Toll-like receptor recognizes bacterial DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Flagellin as an adjuvant: cellular mechanisms and potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

DNA vaccines: designing strategies against parasitic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Vaccination of mice with a cocktail DNA vaccine induces a Th1-type immune response and partial protection against Schistosoma japonicum infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Vaccine adjuvants: putting innate immunity to work

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM? vaccines and conventional vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.587802

10.1517/14712598.2011.587802

21 January 2018

Identifiers

DOI

1 reference

26 March 2018

PubMed ID

21609186

1 reference

26 March 2018